Rhumbline Advisers lifted its stake in Bristol-Myers Squibb Company (NYSE:BMY) by 1.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 2,597,246 shares of the biopharmaceutical company’s stock after acquiring an additional 47,600 shares during the quarter. Rhumbline Advisers owned 0.16% of Bristol-Myers Squibb worth $144,719,000 at the end of the most recent reporting period.
Several other hedge funds also recently modified their holdings of BMY. Ameriprise Financial Inc. lifted its holdings in shares of Bristol-Myers Squibb by 18.7% in the 1st quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after acquiring an additional 2,451,390 shares during the last quarter. Swiss National Bank lifted its holdings in shares of Bristol-Myers Squibb by 27.2% in the 1st quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock worth $322,020,000 after acquiring an additional 1,267,900 shares during the last quarter. State Street Corp lifted its holdings in shares of Bristol-Myers Squibb by 1.8% in the 1st quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after acquiring an additional 1,223,457 shares during the last quarter. Harbour Capital Advisors LLC lifted its holdings in shares of Bristol-Myers Squibb by 5,377.1% in the 2nd quarter. Harbour Capital Advisors LLC now owns 1,189,789 shares of the biopharmaceutical company’s stock worth $21,353,000 after acquiring an additional 1,168,066 shares during the last quarter. Finally, Canada Pension Plan Investment Board lifted its holdings in shares of Bristol-Myers Squibb by 28.4% in the 2nd quarter. Canada Pension Plan Investment Board now owns 4,318,809 shares of the biopharmaceutical company’s stock worth $240,644,000 after acquiring an additional 956,200 shares during the last quarter. Hedge funds and other institutional investors own 68.84% of the company’s stock.
Shares of Bristol-Myers Squibb Company (NYSE:BMY) opened at 64.42 on Monday. The stock has a 50 day moving average of $63.37 and a 200-day moving average of $57.29. The firm has a market capitalization of $105.64 billion, a price-to-earnings ratio of 23.53 and a beta of 1.19. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $66.10.
Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The business had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. During the same period in the previous year, the company posted $0.69 earnings per share. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. On average, equities analysts anticipate that Bristol-Myers Squibb Company will post $2.99 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th will be given a dividend of $0.39 per share. The ex-dividend date is Thursday, October 5th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.42%. Bristol-Myers Squibb’s payout ratio is currently 56.73%.
Several equities analysts have recently commented on the stock. Credit Suisse Group set a $58.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Wednesday, August 16th. BMO Capital Markets restated an “underperform” rating and issued a $47.00 price objective (down from $51.00) on shares of Bristol-Myers Squibb in a report on Wednesday, July 26th. Leerink Swann decreased their price objective on shares of Bristol-Myers Squibb from $66.00 to $61.00 and set an “outperform” rating on the stock in a report on Friday, July 28th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a report on Wednesday, August 9th. Finally, Cowen and Company restated a “hold” rating and issued a $65.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, September 19th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and ten have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $63.79.
In other news, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the transaction, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at $2,777,820. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Theodore R. Samuels II bought 6,000 shares of Bristol-Myers Squibb stock in a transaction dated Wednesday, August 2nd. The shares were purchased at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the transaction, the director now owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The disclosure for this purchase can be found here. Insiders own 0.23% of the company’s stock.
WARNING: “Bristol-Myers Squibb Company (BMY) Stake Boosted by Rhumbline Advisers” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2017/10/23/bristol-myers-squibb-company-bmy-stake-boosted-by-rhumbline-advisers.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.